Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Japan Post-Marketing, Randomized, Double-Blind, Parallel-Group, Flexible Dose Comparative Study to Assess the Non-Inferiority of Duloxetine Compared With Pregabalin in Patients With Diabetic Peripheral Neuropathic Pain

NCT02417935 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT02417935
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02417935 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Japan Post-Marketing, Randomized, Double-Blind, Parallel-Group, Flexible Dose Comparative Study to Assess the Non-Inferiority of Duloxetine Compared With Pregabalin in Patients With Diabetic Peripheral Neuropathic Pain
Lead sponsor
Eli Lilly and Company
Phase
Phase 4
Overall status
Completed
Start date
April 30, 2015
Completion date
May 13, 2017
Enrollment
304 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic peripheral neuropathic pain